


Wesley K. Komane*, Pennie Mokolokolo, Banele Vatsha and Amanda-Lee E. Manicum

The crystal structure of *fac*-tricarbonyl (*N'*-benzoyl-*N,N*-diphenylcarbamimidothioato- $\kappa^2 S,O$)-(pyrazole- κN)rhenium(I) – methanol (1/1) C₂₆H₂₃O₄N₄SRe



<https://doi.org/10.1515/ncrs-2021-0046>

Received January 29, 2021; accepted March 4, 2021;

published online March 17, 2021

Abstract

C₂₆H₂₃O₄N₄SRe, triclinic, $P\bar{1}$ (no. 2), $a = 9.919(2)$ Å, $b = 11.752(3)$ Å, $c = 12.717(3)$ Å, $\alpha = 111.098(7)^\circ$, $\beta = 94.467(7)^\circ$, $\gamma = 98.295(7)^\circ$, $V = 1354.9(5)$ Å³, $Z = 2$, $R_{gt}(F) = 0.0342$, $wR_{ref}(F^2) = 0.0843$, $T = 102.0(2)$ K.

CCDC no.: 2068004

The molecular structure is shown in the Figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

*Corresponding author: Wesley K. Komane, Department of Chemistry, Tshwane University of Technology, Pretoria, 0001, South Africa, E-mail: wkkomane@gmail.com. <https://orcid.org/0000-0002-1892-5787>

Pennie Mokolokolo, Department of Chemistry, University of the Free State, Bloemfontein, 9301, South Africa

Banele Vatsha, Department of Chemistry, University of Johannesburg, Auckland Park, 2006, South Africa

Amanda-Lee E. Manicum, Department of Chemistry, Tshwane University of Technology, Pretoria, 0001, South Africa

Table 1: Data collection and handling.

Crystal:	Yellow cuboid
Size:	0.32 × 0.17 × 0.06 mm
Wavelength:	Mo K α radiation (0.71073 Å)
μ :	4.61 mm ⁻¹
Diffractometer, scan mode:	Bruker APEX-II, φ and ω
θ_{max} , completeness:	28.4°, >99%
$N(hkl)_{measured}$, $N(hkl)_{unique}$, R_{int} :	28,629, 6727, 0.067
Criterion for I_{obs} , $N(hkl)_{gt}$:	$I_{obs} > 2 \sigma(I_{obs})$, 6176
$N(param)_{refined}$:	352
Programs:	Bruker [1], SIR97 [2], Olex2 [3], SHELX [4], Diamond [5]

Source of material

Fac-[Re(S,O)(CO)₃(H₂O)] (S,O = *N'*-benzoyl-*N,N*-diphenylcarbamimidothioate 20 mg, 0.029 mmol) was dissolved in methanol (3 ml) and pyrazole (3.29 mg, 0.00571 mmol) dissolved in (2 ml) methanol was added. The solution was then stirred for 30 min and then refluxed for 24 h at room temperature and the light yellow solution was left to crystallize. (Yield = 15.25 mg, 84%; FTIR (cm⁻¹) ν (CO): 2015, 1889.

Experimental details

All hydrogen atoms were positioned geometrically and refined discernibly using a riding model, with fixed C–H_{Aromatic} = 0.97 Å. The H atoms isotropic displacement parameters were fixed; $U_{iso}(H) = 1.2U_{eq}(C)$ for aromatic, allowing them to ride on the parent atom. The graphics were obtained using the DIAMOND program with 50% probability ellipsoids. All the H-atoms of the title structure were omitted for clarity.

Comment

The chemistry of *fac*-[Re(CO)₃]⁺ precursor has recently drawn attention of several research groups because of its

Table 2: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å²).

	<i>x</i>	<i>y</i>	<i>z</i>	<i>U</i> _{iso} */ <i>U</i> _{eq}
Re1	0.15615 (2)	0.26486 (2)	0.61077 (2)	0.02059 (6)
S1	0.13423 (10)	0.46874 (10)	0.74707 (10)	0.0256 (2)
O4	0.3664 (3)	0.3055 (3)	0.6821 (3)	0.0266 (6)
O2	−0.1446 (3)	0.2264 (3)	0.5100 (3)	0.0363 (8)
O1	0.1892 (4)	0.0175 (3)	0.4294 (3)	0.0473 (10)
N3	0.4193 (3)	0.5187 (3)	0.7938 (3)	0.0232 (7)
O3	0.0642 (4)	0.1328 (4)	0.7692 (3)	0.0426 (9)
N1	0.2368 (4)	0.3666 (4)	0.5072 (3)	0.0263 (8)
N4	0.3080 (3)	0.6801 (3)	0.8412 (3)	0.0214 (7)
O9	0.5471 (4)	0.1927 (4)	0.4341 (4)	0.0519 (10)
N2	0.3377 (4)	0.3371 (4)	0.4425 (4)	0.0357 (9)
C2	−0.0301 (4)	0.2388 (4)	0.5471 (4)	0.0243 (8)
C32	0.6289 (4)	0.2788 (4)	0.7371 (4)	0.0238 (8)
H32	0.566938	0.210060	0.682115	0.029*
C3	0.0987 (5)	0.1825 (4)	0.7086 (4)	0.0287 (9)
C33	0.7604 (5)	0.2659 (4)	0.7690 (4)	0.0285 (9)
H33	0.788788	0.188586	0.735104	0.034*
C7	0.4436 (4)	0.4044 (4)	0.7505 (3)	0.0212 (8)
C31	0.5870 (4)	0.3918 (4)	0.7851 (3)	0.0207 (8)
C11	0.1889 (4)	0.7385 (4)	0.8419 (3)	0.0204 (8)
C34	0.8517 (5)	0.3657 (5)	0.8506 (4)	0.0325 (10)
H34	0.941648	0.356410	0.873265	0.039*
C16	0.1444 (5)	0.7616 (4)	0.7470 (4)	0.0279 (9)
H16	0.190542	0.738956	0.681836	0.034*
C8	0.2972 (4)	0.5551 (4)	0.7921 (3)	0.0202 (8)
C1	0.1771 (4)	0.1104 (4)	0.4981 (4)	0.0295 (9)
C12	0.1242 (5)	0.7729 (4)	0.9379 (4)	0.0296 (9)
H12	0.157561	0.758404	1.003213	0.036*
C35	0.8098 (5)	0.4785 (5)	0.8982 (5)	0.0376 (11)
H35	0.872351	0.547556	0.952203	0.045*
C36	0.6770 (5)	0.4915 (4)	0.8675 (4)	0.0311 (10)
H36	0.647750	0.568217	0.902636	0.037*
C4	0.1875 (5)	0.4534 (5)	0.4804 (5)	0.0365 (11)
H00Q	0.114482	0.491746	0.512520	0.044*
C15	0.0303 (5)	0.8188 (5)	0.7490 (4)	0.0378 (12)
H15	−0.001597	0.835238	0.684432	0.045*
C5	0.2571 (6)	0.4808 (5)	0.3988 (5)	0.0424 (12)
H00S	0.241245	0.538965	0.365348	0.051*
C21	0.4346 (4)	0.7584 (4)	0.9072 (4)	0.0243 (9)
C14	−0.0360 (5)	0.8513 (5)	0.8423 (5)	0.0400 (12)
H14	−0.114006	0.889657	0.842126	0.048*
C26	0.4815 (5)	0.7536 (4)	1.0109 (4)	0.0305 (10)
H26	0.431680	0.696680	1.037661	0.037*
C22	0.5071 (4)	0.8416 (4)	0.8684 (4)	0.0287 (9)
H22	0.475438	0.845396	0.797456	0.034*
C13	0.0100 (5)	0.8288 (5)	0.9381 (5)	0.0365 (11)
H13	−0.036551	0.851448	1.003008	0.044*
C6	0.3530 (6)	0.4059 (5)	0.3774 (5)	0.0458 (13)
H00Y	0.418534	0.402692	0.326200	0.055*
C25	0.6010 (5)	0.8318 (5)	1.0752 (4)	0.0356 (11)
H25	0.633182	0.828552	1.146242	0.043*
C9	0.5515 (7)	0.0657 (6)	0.3820 (6)	0.0563 (16)
H93	0.627847	0.055567	0.336982	0.084*
H91	0.464686	0.022111	0.332147	0.084*
H92	0.565101	0.031071	0.440745	0.084*

Table 2: (continued)

	<i>x</i>	<i>y</i>	<i>z</i>	<i>U</i> _{iso} */ <i>U</i> _{eq}
C23	0.6269 (5)	0.9196 (5)	0.9345 (5)	0.0393 (12)
H23	0.676935	0.977127	0.908576	0.047*
C24	0.6735 (5)	0.9144 (5)	1.0366 (5)	0.0393 (12)
H24	0.755806	0.967739	1.080758	0.047*
H00B	0.394 (6)	0.287 (6)	0.457 (5)	0.049 (17)*
H94	0.624 (12)	0.254 (12)	0.494 (10)	0.16 (5)*

potential use as a therapeutic radiopharmaceutical. This has led to an increased investigation of rhenium metal complexes for their potential use as therapeutic and diagnostic agents [6–9]. Our research group is focusing on the synthesis of rhenium(I) tri- and dicarbonyl complexes for both diagnostic (depending on the type of the bidentate ligand used) and therapeutic applications [10–14]. This is done by coordinating a series of bi- and monodentate ligand systems to a rhenium metal center using a [2+ 1] mixed ligand approach. These coordinating ligands for the structure reported comprises of donor atoms such as sulfur and oxygen.

The molecular structure of the title complex comprises of three facial tricarbonyl ligands, a thiourea bidentate ligand in the equatorial plane which is *trans* to two of the carbonyl ligands and an *N*-coordinated pyrazole monodentate ligand in the axial position. The molecular structure has a guest molecule (methanol solvent) which is omitted for clarity. The bond distances between rhenium and the three carbons of the carbonyl ligands range between 1.894(4) and 1.917(5) Å, whereas Re1–O4, Re1–N1 and Re1–S1 were arranged in an increasing order as follows: 2.123(3), 2.196(4) and 2.452(12) Å, respectively. The results obtained correlate well with other structures already reported in literature by our research group [10, 11] and Warsink [15]. The polyhedron geometry of the complex reveals an octahedral distortion around the rhenium metal center. This distortion is more evident in the bond angles C3–Re1–N1 and C2–Re1–O4 which were reported as 175.64(16)° and 176.38(14)° respectively. The bite angle of the title structure was found to be 87.67(8)° and deviated slightly from the bite angle of a similar bidentate ligand coordinated to rhodium reported by Warsink (91.1(1)°) [15].

The molecules are arranged in a head-to-head manner and are stabilized by couple of intra- and intermolecular hydrogen bonds.

Acknowledgements: We would like to acknowledge Tshwane University of Technology for Institutional support.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: The authors would like to express the gratitude towards NRF (Thuthuka grant specific number 113629) for financial assistance.

Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Bruker. *SAINT-Plus* (version 7.12) and *SADABS* (Version 2004/1); Bruker AxS Inc.: Madison, Wisconsin, USA, 2004.
2. Altomare A., Burla M. C., Camalli M., Cascarano G. L., Giacovazzo C., Guagliardi A., Moliterni A. G. G., Polidori G., Spagna R. SIR97: a new tool for crystal structure determination and refinement. *J. Appl. Crystallogr.* 1999, 32, 115–119.
3. Dolomanov O. V., Bourhis L. J., Gildea R. J., Howard J. A. K., Puschmann H. OLEX2: a complete structure solution, refinement and analysis program. *J. Appl. Crystallogr.* 2009, 42, 339–341.
4. Sheldrick G. M. A short history of *SHELX*. *Acta Crystallogr.* 2008, A64, 112–122.
5. Brandenburg K., Putz H. *DIAMOND. Visual Crystal Structure Information System*. Ver. 3.0c; Crystal Impact GbR: Bonn, Germany, 2005.
6. Brink A., Helliwell J. R. New leads for fragment-based design of rhenium/technetium radiopharmaceuticals agents. *IUCrj* 2017, 3, 283–290.
7. Aimene Y., Eychene R., Mallet-Ladeira S., Saffon N., Winum J. Y., Nocentini A., Supuran C. T., Benoist E., Seridi A. Novel Re(I) tricarbonyl complexes based on 2-pyridyl-1,2,3-triazole derivatives bearing a 4-amino-substituted benzenesulfonamide arm: synthesis, crystal structure, computational studies and inhibitory activity against carbonic anhydrase I, II and IX isoforms. *J. Enzym. Inhib. Med. Chem.* 2019, 34, 773–782.
8. Zobi F. A different spin on rhenium chemistry. synthetic approaches and perspectives of 17-electron rhenium complexes. *Chem. Rev.* 2010, 4, 259–265.
9. Lepareur N., Lacoëuille F., Bouvry C., Hindre F., Carcion E., Cherel M., Noiret N., Garin E., Knapp F. F. Rhenium-188 labelled radiopharmaceuticals: current clinical applications in oncology and promising perspectives. *Front. Med.* 2019, 6, 132 (19 pages).
10. Ramoba L. V., Alexander O. T., Visser H. G., Manicum A. The crystal structure of *fac*-tricarbonyl(1.10-phenanthroline- κ^2N,N')-(pyrazole- κN)rhenium(I)nitrate, $C_{18}H_{16}O_3N_4Re$. *Z. Kristallogr. NCS* 2020, 235, 1203–1205.
11. Moremi M. J., Alexander O. T., Vatsa B., Makgopa K., Manicum A. The crystal structure of *fac*-tricarbonyl(4,4-dimethyl-2,2-dipyridyl- κ^2-N,N')(pyrazole- κN)rhenium(I)nitrate, $C_{18}H_{12}O_3N_4Re$. *Z. Kristallogr. NCS* 2020, 236, 33–35.
12. Manicum A. E., Schutte-Smith M., Visser H. G. The synthesis and structural comparison of *fac*-[Re(CO)₃]⁺ containing complexes with altered β -diketone and phosphine ligands. *Polyhedron* 2018, 145, 80–87.
13. Manicum A. E., Schutte-Smith M., Kemp G., Visser H. G. Illustration of the electronic influence of coordinated β -diketone type ligands: a kinetic study. *Polyhedron* 2015, 85, 190–195.
14. Manicum A. E., Schutte-Smith M., Visser H. G., Pretorius C., Roodt A. The crystal structure tetraethyl ammonium *fac*-tricarbonyl(hexafluoroacetylacetonato- κ^2O,O')-(nitrate- κO)rhenium(I), $C_{16}H_{21}N_2F_6Re$. *Z. Kristallogr. NCS* 2016, 231, 263–266.
15. Warsink S., Riekert K., Janse Van Rensburg J. M., Venter J. A., Otto S., Botha E., Roodt A. Kinetic-mechanistic and solid-state study of the oxidative addition and migratory insertion of iodomethane to [Rhodium(*S,O-BdiPT* or *N,O-ox*)(CO)($PR^1R^2R^3$)] complexes. *Eur. J. Inorg. Chem.* 2018, 2018, 3615–3625.